iModels Biology (Beijing) Co., Ltd., a CRO service provider of tumor and tumor immunopharmacodynamic evaluation, recently announced that it had secured an investment of tens of millions of yuan. The investment was led by ZGC Collaborative Innovation Fund and followed by Zhongbo Capital.

Funds raised from this round will be mainly used to support the current construction of new laboratory facilities and the development of new preclinical research platform.